Imatinib Mesylate News and Research

RSS
Imatinib mesylate (also called Gleevec® or STI571) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of some forms of adult and pediatric chronic myelogenous leukemia (CML), and for the treatment of a rare form of cancer called gastrointestinal stromal tumor (GIST).

With CML, imatinib works by blocking an abnormal enzyme characteristic of the disease. In GIST, imatinib blocks a different abnormal enzyme found on the tumor cells.

Imatinib is the first approved drug to directly turn off the signal of a protein known to cause a cancer. Other molecular-targeting drugs previously approved by the FDA interfere with proteins associated with other cancers, but not with proteins that directly cause the disease.

Imatinib is being investigated for its effectiveness against other kinds of cancer, as well, including acute lymphocytic leukemia and hypereosinophilic syndrome (HES).
Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

FDA approves SUTENT for treatment of pancreatic NET

FDA approves SUTENT for treatment of pancreatic NET

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Pfizer ceases SUN 1120 Phase 3 trial of SUTENT in men with CRPC

Pfizer ceases SUN 1120 Phase 3 trial of SUTENT in men with CRPC

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

Pfizer reports Progression-Free survival in SUN 1087 combination trial of sunitinib with erlotinib for NSCLC

Tasigna receives approval for chronic myeloid leukemia in Canada

Tasigna receives approval for chronic myeloid leukemia in Canada

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Combination therapy proves to be effective treatment for lethal form of leukemia: Research

Combination therapy proves to be effective treatment for lethal form of leukemia: Research

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Study: Trial vaccine eliminates residual cancer cells in CML patients

Study: Trial vaccine eliminates residual cancer cells in CML patients

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Two Phase 3 studies of Sutent in advanced breast cancer fail to meet primary endpoints

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

Positive results from BioSante Pharmaceuticals' GVAX Leukemia vaccine human clinical study

EpiCept provides business update and fourth-quarter financial highlights

EpiCept provides business update and fourth-quarter financial highlights

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML

Novartis' Tasigna capsules granted priority review by FDA for treatment of adult patients with Ph+ CML